Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.01918-24 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von D Yitzchak Goldstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Medical Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomaviridae, Cervix Uteri, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Incorporating molecular testing for human papillomavirus (HPV) into the screening of cervical specimens can improve risk stratification and, in turn, patient management. Infection with a high-risk (HR) HPV genotype is associated with greater risk for persistent infection, viral integration, and progression of cervical neoplasia. Current guidelines consider HPV 16 or HPV 18 clinically actionable with referral to colposcopy; however, 12 Other HR HPV genotypes have been associated with cervical cancer risk, suggesting a benefit of extended genotyping. In this multi-center study, we evaluated the performance of the Alinity m HR HPV assay, which reports HPV 16, 18, and 45 individually and aggregates of HPV 31/33/52/58 and HPV 35/39/51/56/59/66, compared with cobas HPV and Aptima HPV assays, across a variety of cytology result categories. A total of 746 de-identified residual cervical specimens, collected as part of routine cervical cancer screening programs, were tested using Alinity m HR HPV and at least one comparator assay. The overall percent agreement was ≥90.7% for results from the Alinity m HR HPV assay and cobas HPV assays and 90.5% for results from the Alinity m HR HPV and Aptima HPV assay. In patients with any abnormal cytology result, Alinity m identified 78 specimens with non-HPV 16/18 results, underscoring the benefit of detecting additional HR HPV genotypes to guide patient management more accurately. Among specimens with normal cytology, Alinity m detected 14 additional specimens with non-HPV 16/18 genotypes. Extended HR HPV testing can provide additional information to triage patients for appropriate testing and follow-up. IMPORTANCE Extended genotyping for high-risk human papillomavirus (HPV) types enhances diagnostic precision by identifying additional oncogenic HPV types beyond 16 and 18 therefore offering a more nuanced risk profile. This more comprehensive detection may aid in identifying persistent infections that are more likely to progress, thereby supporting future risk-based patient management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Montefiore Medical Center, Bronx, New York, USA.
- Ochsner Health, New Orleans, Louisiana, USA.
- Molecular Diagnostics of Abbott, Des Plaines, Illinois, USA.
- PathAI Diagnostics, Memphis, Tennessee, USA.
ORCID-Profile: D Yitzchak Goldstein, Joshua Kostera
Zitieren
APA
Goldstein, D. Y., Yang, T., Lucic, D., Zhang, Y., Cullum, R., Kostera, J., & Patel, A. (2025). Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01918-24
Vancouver
Goldstein DY, Yang T, Lucic D, Zhang Y, Cullum R, Kostera J, et al. Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01918-24
BibTeX
@article{Goldstein2025,
author = {Goldstein, D Yitzchak and Yang, Tong and Lucic, Danijela and Zhang, Yan and Cullum, Richard and Kostera, Joshua and Patel, Anami},
title = {Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.01918-24}
}
EUVIMED